Skip to content

Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis

Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis Indicated for the Treatment of Primary and Secondary First Line Gonarthrosis and Revision Arthroplasty - 2 Years Follow-up - A Pilot Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06124482
Acronym
FHK-CK
Enrollment
92
Registered
2023-11-09
Start date
2024-02-01
Completion date
2028-02-29
Last updated
2025-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Knee Arthroplasty

Keywords

Complex primary Total Knee Arthroplasty, Revision Total Knee Arthroplasty, Functional performance, Safety evaluation

Brief summary

The life expectancy worldwide is increasing and leading to an increase of knee arthroplasty. Also, as millions of people around the world are currently living with a Total Knee Arthroplasty (TKA), the need for revision surgery represents a large public health burden. In this context, FH ORTHO company develops FHK®-CK (prosthesis + ancillary equipment) which is a knee prosthesis for complex first intention and revision knee arthroplasty. This new medical device complements the FHK® standard first-line range (CE marked). The FHK®-CK ancillary equipment were designed by expert knee surgeons and is simple, reliable and reproducible. It allows for maximum versatility while remaining compact. By completing the FHK® range of first intention prostheses, the FHK®-CK allows the surgeon to be on the same level as the competitors by having a first intention and semi-constrained prosthesis. This prosthetic arsenal allows the surgeon to opt for the best solution for his patient so that he can regain mobility and a satisfactory quality of life. Also, in case of failure of the FHK® first-line prosthesis, it will provide the surgeon and the patient with a simple alternative to prosthesis replacement. As it has been developed in line with the first intention, inter-compatibility between the two systems is possible, which simplifies the surgical procedure and reduces the risks for the patient.

Interventions

DEVICETotal Knee arthroplasty

The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.

Sponsors

Slb Pharma
CollaboratorOTHER
FH ORTHO
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Two target populations will be included in this clinical investigation : * 60 patients requiring primary Total Knee Arthroplasty * 32 patients requiring revision Knee Arthroplasty. In this clinical investigation, it was not possible to realize a double-blinding for practical reasons. Nevertheless, a collection of the primary outcome (score KSS) will be realized blindly to the surgeon in charge of the patient by an intervener not involved in the medical care of the patient, who did not participate in the intervention and did not collect the preoperative KSS score.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient requiring knee arthroplasty for primary or secondary gonarthrosis: \* For primary intention arthroplasty: Patient with either * major axial deviation, * major peripheral failure or * bone defect; \* For prosthesis revision surgery: Patient who have had a failed 1st implantation, with or without bone defects. * Patient able to understand and answer the questionnaires provided by the protocol; * Subject affiliated to a health insurance system or is a beneficiary; * Signed informed consent form (ICF) for participation to the research.

Exclusion criteria

* Patient with an ongoing acute infection, outside knee to be operated; * Patient with a mental or neuromuscular disorder that would create an unacceptable risk of prosthetic instability, prosthetic fixation failure or post-operative complications; * Patient with a known allergy to any of the components of the FHK®-CK implants (Nickel, Cobalt, Chromium); * Patient with a dependency (drug, alcohol,…) that could affect his/ her ability to comply with the protocol, at the investigator's discretion; * Patient requiring knee reconstruction; * Patient with any medically significant findings or significant history that may impact the safety, interpretation of results, and/ or participation of the subject in the clinical trial, as determined by the investigator; * Patient with an existing knee or hip prosthesis (outside knee to be operated) that may impact the evaluation of the FHK®-CK prosthesis; * Patient concurrently participating in another clinical trial or who has recently participated in another clinical trial for which the exclusion period has not been completed. * Vulnerable subjects : * Pregnant, parturient, or breastfeeding women, * Subject deprived of liberty, hospitalized without consent or admitted to a health or social establishment for purposes other than that of research, * Minor, * Adult under protective supervision (tutorship, curatorship), * Subject not able to understand the subject information leaflet (e.g. for linguistic or psychiatric reasons) and/or to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Functional performanceBaseline (preoperatively), at 6 weeks, 6 months, 12 months and 24 months after surgery.Evolution of the functional performance of FHK®-CK prosthesis using the KSS scoring system, which is composed of 2 sections : Knee score (KSKS) and function score (KSFS). Each section is scored on a scale of 0 to 100 ; the higher the score, the better the overall functionality of the knee. The functional performance of the FHK®-CK prosthesis will be demonstrated at 2 years if an improvement of the KSKS and KSFS scores at least equal to the Minimal Clinically Important Difference (MCID) values is observed.

Secondary

MeasureTime frameDescription
Revision rate evaluationAt 6 weeks, 6 months, 12 months and 24 months after surgery.Revision rate
Evaluation of patient's tolerance of the FHK-CK prosthesisAt 6 weeks, 6 months, 12 months and 24 months after surgery.Tolerance assessed by the surgeon with a 4-Likert scale (very bad - bad - good - very good)
Device deficiencies evaluationThrough study completion, an average of 2 yearsNumber of device deficiencies and description of deficiencies.
Adverse and serious adverse events evaluationThrough study completion, an average of 2 yearsOccurrence of adverse and serious adverse events, including complication
Patient's satisfaction about FHK®-CK prosthesisAt 6 months, 12 months and 24 months after surgerySatisfaction assessed by the patient with a 4-Likert scale ((very bad - bad - good - very good)
Surgeon's satisfaction about FHK®-CK equipmentDuring surgerySatisfaction assessed by the surgeon for each surgery performed with FHK®-CK with a specific questionnaire developed including 9 questions with either a lickert scale or a yes/no response.
Quality of life assessmentBaseline (preoperatively), at 6 months, 12 months and 24 months after surgery.Self assessement of quality of life using the medical outcome study Short Form (SF-12) scale (General Quality of life score) from 0 worst quality of life to 100 best quality of life.

Countries

France

Contacts

Primary ContactCarole CARRÉ
c.carre@fhortho.com06 40 47 16 71
Backup ContactDelphine KORNER
d.korner@fhortho.com07 87 86 29 14

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026